Publications by authors named "Sandra R Brackert"
Clin Cancer Res
January 2022
Article Synopsis
- - The study evaluated the effects of nivolumab (N) alone and nivolumab combined with ipilimumab (N + I) on patients with advanced gastrointestinal stromal tumors (GIST) who were resistant to prior treatment with imatinib.
- - Out of 36 patients, the objective response rate was not higher than 15%; N showed a clinical benefit rate of 52.6% with a median progression-free survival of 11.7 weeks, while N + I had a lower clinical benefit rate of 31.3% and a median progression-free survival of 8.3 weeks.
- - Despite not meeting the primary endpoint, some patients experienced long-term disease control, and both treatment reg
